Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Instagram Outage Disrupts Thousands of U.S. Users 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
U.S. Stock Futures Edge Higher as Tech Rout Deepens on AI Concerns and Earnings 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Asian Markets Slip as AI Spending Fears Shake Tech, Wall Street Futures Rebound 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Thailand Inflation Remains Negative for 10th Straight Month in January 
Novartis AG is a Switzerland-based pharmaceutical company that ranks in the top 5 largest pharma brands in the world. It has recently acquired the American biotech firm, Chinook Therapeutics, for $3.5 billion.
Novartis confirmed on Monday, June 12, that it has agreed to a deal that will merge its new subsidiary with Chinook Therapeutics. According to Reuters, the transaction between the companies is expected to be completed by the second half of this year.
Then again, the merger deal is still subject to customary closing conditions. It was also mentioned that this move is completely in accordance with Novartis’ strategy to point its attention to innovative medicines. The buyout will also expand the company’s renal portfolio.
The Swiss pharma further explained that it will acquire the Seattle, Washington-headquartered clinical biotech firm with two high-value, late-stage medicines in development for rare, chronic kidney diseases. Under the contract, shareholders of Chinook will receive $3.2 billion, which is equivalent to $40 per share, in cash. Novartis added that shareholders will also get a contingent value right worth up to $300 million, which will depend on some regulatory achievements.
Meanwhile, Chinook Therapeutics is looking to report data from the last phase of research for its experimental oral drug called Atrasentan, which is used to treat a kidney disease known as IgAN, in the Q4 of 2023. It is currently working on another experimental injectable version of the IgAN treatment called Zigakibart. A late-stage trial for these treatments is set to begin in the third quarter of this year.
“IgA Nephropathy is a devastating disease mostly affecting young adults and potentially leading to dialysis or kidney transplantation,” Novatis’ chief executive officer, Vas Narasimhan, M.D., said in a press release. “We are excited by this unique opportunity to address one of society’s most challenging healthcare issues, with the potential to bring additional much-needed treatment options to patients. We look forward to closing the deal, to a smooth transition for Chinook employees and to welcoming them to Novartis.”
Photo by: Novartis Media Gallery
